Document resource
Cancer clinical trials form the foundation for the approval and use of new anticancer therapies. Alongside traditional endpoints such as survival and tumour response, patient-reported outcomes (PROs) are now a cornerstone of oncology trials and are increasingly expected by regulators.1 By capturing symptoms and functional health directly from patients, PROs provide essential information for patient-focused drug development and shared decision-making.